arrow
S

Shinya Kajiura

University of Toyama
H指数:14
被引数:766

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Three-month follow-up of high-dose intravenous iron monotherapy for cancer-related anemia in an ESA-free oncology setting: a real-world cohort study

癌症相关贫血在无促红细胞生成素(ESA)肿瘤科环境中高剂量静脉铁单药治疗的三个月随访:一项真实世界队列研究

2026-07-040
PRE
Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis

日本临床肿瘤学会专科医师在机构层面的可用性与记录的胰腺癌一线治疗过程持续时间:一项全国癌症基因组学和先进治疗中心登记分析

2026-07-020
OAAI
Shakuyakukanzoto for Paclitaxel-Induced Myalgia and Arthralgia: A Placebo-Controlled Crossover Trial

芍药甘草汤对紫杉醇诱导的肌痛和关节痛的疗效:一项安慰剂对照交叉试验

2026-04-210
PRE
Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: a secondary analysis of a randomized clinical trial

纳多美定在癌症疼痛患者初次使用阿片类药物时的新的止吐效果:一项随机临床试验的二次分析

2026-04-010
PRE
Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)

盐酸安莫妙早期停药预测因素:胃肠道癌相关恶病质的多中心回顾性队列研究(HGCSG2201)

2026-02-190
PRE
Update analysis of the randomized phase II study comparing FOLFIRI plus ramucirumab (RAM) versus FOLFOXIRI plus RAM as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST)

对比较FOLFIRI联合ramucirumab(RAM)与FOLFOXIRI联合RAM作为转移性结直肠癌患者一线治疗的随机II期研究的更新分析:WJOG9216G(RECAST)

2024-09-010
PRE
Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): Subgroup analyses of WJOG9216G (RECAST)

年龄和单杂合UGT1A1对含雷莫芦单抗(RAM)的转移性结直肠癌(mCRC)一线FOLFIRI或FOLFOXIRI方案的安全性和有效性的影响:WJOG9216G (RECAST)的亚组分析

2024-09-010
PRE